Literature DB >> 16390811

T cell targeted immunotherapy for autoimmune disease.

Erica Lee1, Animesh A Sinha.   

Abstract

Much emphasis has been placed on the so-called "biologics" in the treatment of immune disorders within the last few years. Here we discuss the expanding horizon of potential strategies for immunotherapies targeting T lymphocytes as key effectors and regulators of autoimmunity. We review emerging reagents in a variety of animal models and human disorders that may offer new therapeutic options in current or modified iterations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16390811     DOI: 10.1080/08916930500418136

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  2 in total

1.  Prediction of desmoglein-3 peptides reveals multiple shared T-cell epitopes in HLA DR4- and DR6-associated pemphigus vulgaris.

Authors:  Joo Chuan Tong; Tin Wee Tan; Animesh A Sinha; Shoba Ranganathan
Journal:  BMC Bioinformatics       Date:  2006-12-18       Impact factor: 3.169

2.  Priming of autoreactive CD8(+) T cells is inhibited by immunogenic peptides which are competitive for major histocompatibility complex class I binding.

Authors:  Sooseong You; Yoon Seok Choi; Seokchan Hong; Eui-Cheol Shin
Journal:  Immune Netw       Date:  2013-06-30       Impact factor: 6.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.